MDS Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for mds in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

    The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

    Stage
    Not phased
    Ages
    60 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    Abramson Cancer Center at Penn Medicine

    See if you can join NCT03680677 on ClinicalTrials.gov

  2. A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

    This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    26 in total
    Run by
    TScan Therapeutics, Inc.

    See if you can join NCT07702578 on ClinicalTrials.gov

  3. A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

    This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with A…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    21 in total
    Run by
    TScan Therapeutics, Inc.

    See if you can join NCT05473910 on ClinicalTrials.gov

  4. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

    Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

    Stage
    Phase 1
    Ages
    1 to 21
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Locations
    31 in total
    Run by
    Therapeutic Advances in Childhood Leukemia Consortium

    See if you can join NCT05476770 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.